[SCHEDULE 13D/A] Bausch Health Companies Inc SEC Filing
Bausch Health Companies Inc.'s Schedule 13D Amendment No. 7 reports that the group of Icahn-related reporting persons sold substantial holdings and now hold no beneficial interest in the issuer's common stock. On August 14, 2025, Icahn Partners LP sold 20,297,523 shares and Icahn Partners Master Fund LP sold 14,423,595 shares, each at a price of $9.00 per share (including brokerage fees). Following these transactions the reporting persons may be deemed to beneficially own 0 shares and have ceased to be beneficial owners of more than 5% of the class, removing their obligation to report under Rule 13d-1(a).
La Schedule 13D Emendamento n. 7 di Bausch Health Companies Inc. segnala che il gruppo di soggetti dichiaranti collegati a Icahn ha venduto partecipazioni significative e ora non detiene alcun interesse di natura beneficiaria nelle azioni ordinarie dell'emittente. In data 14 agosto 2025, Icahn Partners LP ha venduto 20.297.523 azioni e Icahn Partners Master Fund LP ha venduto 14.423.595 azioni, entrambe al prezzo di $9,00 per azione (comprese le commissioni di intermediazione). A seguito di tali transazioni, i soggetti dichiaranti possono essere considerati titolari benefici di 0 azioni e hanno cessato di essere beneficiari di oltre il 5% della classe, eliminando l'obbligo di segnalazione ai sensi della Rule 13d-1(a).
La Enmienda No. 7 del Schedule 13D de Bausch Health Companies Inc. informa que el grupo de informantes vinculados a Icahn vendi贸 participaciones sustanciales y ya no posee inter茅s beneficiario en las acciones comunes del emisor. El 14 de agosto de 2025, Icahn Partners LP vendi贸 20.297.523 acciones e Icahn Partners Master Fund LP vendi贸 14.423.595 acciones, cada una a un precio de $9,00 por acci贸n (incluidas las comisiones de corretaje). Tras estas operaciones, los informantes pueden ser considerados poseedores beneficiarios de 0 acciones y han dejado de ser propietarios beneficiarios de m谩s del 5% de la clase, lo que elimina su obligaci贸n de informar conforme a la Rule 13d-1(a).
Bausch Health Companies Inc.鞚� Schedule 13D 鞝�7彀� 靾橃爼靹滌棎 霐半ゴ氅�, Icahn 甏�霠� 鞁犼碃鞚� 攴鸽９鞚� 靸侂嫻頃� 歆�攵勳潉 毵り皝頃橃棳 氚滍枆須岇偓鞚� 氤错喌欤检棎 雽�頃� 鞁れ鞝� 鞚挫澋鞚� 雿� 鞚挫儊 氤挫湢頃橃 鞎婈矊 霅橃棃鞀惦媹雼�. 2025雲� 8鞗� 14鞚� Icahn Partners LP電� 20,297,523欤�毳�, Icahn Partners Master Fund LP電� 14,423,595欤�毳� 臧侁皝 欤茧嫻 $9.00(欷戧皽 靾橃垬耄� 韽暔)鞐� 毵る弰頄堨姷雼堧嫟. 鞚措煬頃� 瓯半灅 鞚错泟 鞁犼碃鞚鸽摛鞚� 0欤�毳� 鞁れ 氤挫湢頃� 瓴冹溂搿� 臧勳＜霅� 靾� 鞛堨溂氅�, 頃措嫻 瓿勱笁鞚� 5% 齑堦臣 鞁れ唽鞙犾瀽 歆�鞙勱皜 靻岆└霅橃柎 Rule 13d-1(a)鞐� 霐半ジ 氤搓碃 鞚橂霃� 鞐嗢柎臁岇姷雼堧嫟.
L'amendement n掳7 du Schedule 13D de Bausch Health Companies Inc. indique que le groupe de personnes d茅clarantes li茅es 脿 Icahn a vendu des participations substantielles et ne d茅tient d茅sormais aucun int茅r锚t b茅n茅ficiaire dans les actions ordinaires de l'茅metteur. Le 14 ao没t 2025, Icahn Partners LP a vendu 20 297 523 actions et Icahn Partners Master Fund LP a vendu 14 423 595 actions, chacune au prix de 9,00 $ par action (frais de courtage inclus). 脌 la suite de ces op茅rations, les d茅clarants peuvent 锚tre r茅put茅s d茅tenir 0 action et ont cess茅 d'锚tre d茅tenteurs b茅n茅ficiaires de plus de 5 % de la cat茅gorie, ce qui supprime leur obligation de d茅claration en vertu de la Rule 13d-1(a).
Die Schedule 13D 脛nderung Nr. 7 von Bausch Health Companies Inc. berichtet, dass die Gruppe der Icahn-verbundenen Meldenden nennenswerte Best盲nde ver盲u脽ert hat und nun kein wirtschaftliches Interesse an den Stammaktien des Emittenten mehr h盲lt. Am 14. August 2025 verkaufte Icahn Partners LP 20.297.523 Aktien und Icahn Partners Master Fund LP 14.423.595 Aktien, jeweils zu einem Preis von $9,00 pro Aktie (einschlie脽lich Maklergeb眉hren). Nach diesen Transaktionen k枚nnen die meldenden Personen als wirtschaftliche Eigent眉mer von 0 Aktien angesehen werden und haben aufgeh枚rt, wirtschaftliche Eigent眉mer von mehr als 5% der Klasse zu sein, wodurch ihre Meldepflicht gem盲脽 Rule 13d-1(a) entf盲llt.
- Transaction completed: The filing confirms completion of large share sales on August 14, 2025.
- Clear pricing disclosed: Sales executed at $9.00 per share, including brokerage fees.
- Loss of significant ownership: Reporting persons reduced holdings to 0 shares and ceased to be >5% owners.
- Large block disposition: Total reported sales of 34,721,118 shares represent a material change in ownership.
Insights
TL;DR Large block sales by the Icahn group reduced their holdings to zero, a materially disclosable change that removes their >5% reporting status.
The filing documents two sizable disposals totaling 34,721,118 shares sold at $9.00 per share. From a market-disclosure perspective this is material: it changes the ownership register and eliminates the group's reporting obligations under Rule 13d-1(a). The disclosure is concise and factual; it does not state reasons for the sales or any related agreements. For investors, the key facts are the number of shares, the per-share price, and the resulting 0 share beneficial ownership.
TL;DR The departure of an activist-sized holder is a material governance event, primarily factual in this filing.
This amendment confirms the reporting persons no longer hold shares above the 5% threshold following the August 14, 2025 sales. The filing is limited to ownership and sale mechanics; it contains no commentary on board, strategic or governance implications. From a governance standpoint, removal of an activist shareholder could change engagement dynamics, but the filing offers no direct evidence of follow-on actions or agreements.
La Schedule 13D Emendamento n. 7 di Bausch Health Companies Inc. segnala che il gruppo di soggetti dichiaranti collegati a Icahn ha venduto partecipazioni significative e ora non detiene alcun interesse di natura beneficiaria nelle azioni ordinarie dell'emittente. In data 14 agosto 2025, Icahn Partners LP ha venduto 20.297.523 azioni e Icahn Partners Master Fund LP ha venduto 14.423.595 azioni, entrambe al prezzo di $9,00 per azione (comprese le commissioni di intermediazione). A seguito di tali transazioni, i soggetti dichiaranti possono essere considerati titolari benefici di 0 azioni e hanno cessato di essere beneficiari di oltre il 5% della classe, eliminando l'obbligo di segnalazione ai sensi della Rule 13d-1(a).
La Enmienda No. 7 del Schedule 13D de Bausch Health Companies Inc. informa que el grupo de informantes vinculados a Icahn vendi贸 participaciones sustanciales y ya no posee inter茅s beneficiario en las acciones comunes del emisor. El 14 de agosto de 2025, Icahn Partners LP vendi贸 20.297.523 acciones e Icahn Partners Master Fund LP vendi贸 14.423.595 acciones, cada una a un precio de $9,00 por acci贸n (incluidas las comisiones de corretaje). Tras estas operaciones, los informantes pueden ser considerados poseedores beneficiarios de 0 acciones y han dejado de ser propietarios beneficiarios de m谩s del 5% de la clase, lo que elimina su obligaci贸n de informar conforme a la Rule 13d-1(a).
Bausch Health Companies Inc.鞚� Schedule 13D 鞝�7彀� 靾橃爼靹滌棎 霐半ゴ氅�, Icahn 甏�霠� 鞁犼碃鞚� 攴鸽９鞚� 靸侂嫻頃� 歆�攵勳潉 毵り皝頃橃棳 氚滍枆須岇偓鞚� 氤错喌欤检棎 雽�頃� 鞁れ鞝� 鞚挫澋鞚� 雿� 鞚挫儊 氤挫湢頃橃 鞎婈矊 霅橃棃鞀惦媹雼�. 2025雲� 8鞗� 14鞚� Icahn Partners LP電� 20,297,523欤�毳�, Icahn Partners Master Fund LP電� 14,423,595欤�毳� 臧侁皝 欤茧嫻 $9.00(欷戧皽 靾橃垬耄� 韽暔)鞐� 毵る弰頄堨姷雼堧嫟. 鞚措煬頃� 瓯半灅 鞚错泟 鞁犼碃鞚鸽摛鞚� 0欤�毳� 鞁れ 氤挫湢頃� 瓴冹溂搿� 臧勳＜霅� 靾� 鞛堨溂氅�, 頃措嫻 瓿勱笁鞚� 5% 齑堦臣 鞁れ唽鞙犾瀽 歆�鞙勱皜 靻岆└霅橃柎 Rule 13d-1(a)鞐� 霐半ジ 氤搓碃 鞚橂霃� 鞐嗢柎臁岇姷雼堧嫟.
L'amendement n掳7 du Schedule 13D de Bausch Health Companies Inc. indique que le groupe de personnes d茅clarantes li茅es 脿 Icahn a vendu des participations substantielles et ne d茅tient d茅sormais aucun int茅r锚t b茅n茅ficiaire dans les actions ordinaires de l'茅metteur. Le 14 ao没t 2025, Icahn Partners LP a vendu 20 297 523 actions et Icahn Partners Master Fund LP a vendu 14 423 595 actions, chacune au prix de 9,00 $ par action (frais de courtage inclus). 脌 la suite de ces op茅rations, les d茅clarants peuvent 锚tre r茅put茅s d茅tenir 0 action et ont cess茅 d'锚tre d茅tenteurs b茅n茅ficiaires de plus de 5 % de la cat茅gorie, ce qui supprime leur obligation de d茅claration en vertu de la Rule 13d-1(a).
Die Schedule 13D 脛nderung Nr. 7 von Bausch Health Companies Inc. berichtet, dass die Gruppe der Icahn-verbundenen Meldenden nennenswerte Best盲nde ver盲u脽ert hat und nun kein wirtschaftliches Interesse an den Stammaktien des Emittenten mehr h盲lt. Am 14. August 2025 verkaufte Icahn Partners LP 20.297.523 Aktien und Icahn Partners Master Fund LP 14.423.595 Aktien, jeweils zu einem Preis von $9,00 pro Aktie (einschlie脽lich Maklergeb眉hren). Nach diesen Transaktionen k枚nnen die meldenden Personen als wirtschaftliche Eigent眉mer von 0 Aktien angesehen werden und haben aufgeh枚rt, wirtschaftliche Eigent眉mer von mehr als 5% der Klasse zu sein, wodurch ihre Meldepflicht gem盲脽 Rule 13d-1(a) entf盲llt.
FAQ
How many BHC shares did the Icahn group sell on August 14, 2025?
At what price were the BHC shares sold according to the Schedule 13D/A?
Do the Icahn reporting persons still beneficially own more than 5% of BHC?
Does the filing state reasons for the sale or any agreements related to the transactions?
Which rule's reporting obligation did the reporting persons cease to be subject to?
